Please assess the completion status of the following clinical trial:

Trial Title: Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~Inclusion criteria:~* Histologically or cytologically confirmed relapsed or chemotherapy/immunotherapy-resistant mantle cell lymphoma~  * No more than 3 lines of prior systemic treatment~* At least one measurable lesion ≥ 15 mm in its greatest transverse diameter by CT scan~Exclusion criteria:~* Presence or history of CNS disease (either CNS lymphoma or lymphomatous meningosis)~* Newly diagnosed mantle cell lymphoma~* Patients suitable for intensive treatment (e.g., hyperfractionated cyclophosphamide, vincristine, doxorubicin hydrochloride and dexamethasone with high-dose methotrexate and cytarabine \[HyperCVAD\])~PATIENT CHARACTERISTICS:~Inclusion criteria:~* WHO performance status ≤ 2~* Creatinine clearance ≥ 30mL/min~* Bilirubin ≤ 2 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 2 times ULN~* AST and ALT ≤ 2 times ULN~* Neutrophils ≥ 1,500/mm³ (≥ 1,000/mm³ with marrow infiltration)~* Thrombocytes ≥ 100,000/mm³ (≥ 75,000/mm³ in case of bone marrow infiltration)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 12 months after study participation~Exclusion criteria:~* Prior or concurrent hematological malignancies~  * Patients with prior solid organ tumors that required no treatment over the last 5 years and are currently free of disease are eligible~* Cardiovascular disease including any of the following:~  * NYHA class III or IV congestive heart failure~ * Unstable angina pectoris~ * Significant arrhythmia or arrhythmia requiring chronic treatment~ * Myocardial infarction in the last 3 months~* Serious underlying medical condition which could impair the ability of the patient to participate in the trial including any of the following:~  * Uncontrolled diabetes mellitus~ * Gastric ulcers~ * Active autoimmune disease~ * Ongoing infection (e.g., HIV or hepatitis)~PRIOR CONCURRENT THERAPY:~Exclusion criteria:~* Prior radiation where the indicator lesion(s) are in the irradiated field~* Prior organ transplantation~* Participation in another clinical trial within 30 days prior to study entry~* Concurrent anticancer drugs/treatments or experimental medications~* Other concurrent investigational therapy~* Other concurrent chemotherapy, immunotherapy, or radiotherapy (including palliative radiotherapy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus (Type: EXPERIMENTAL): Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).